Program
DR10624
A development code. Also written as “DR10624 Injection”, “DR10624 for injection” and “DR10624 Subcutaneous Injection”.
Its studies are mostly in Hypertriglyceridemia · Obesity, Metabolically Benign · Non-alcoholic Fatty Liver Disease, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 64 open or running | phase 3since Jun 24, 2026 | Mar 25, 2022 | Apr 2028phase 2 · NCT07848880 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2022First study: phase 1 study in Obesity, Metabolically BenignFirst studyNCT05378893 · 153 enrolled · New Zealand
- Jul 30, 2024Phase 2 study in HypertriglyceridemiaNCT06555640 · 79 enrolled · China
- Apr 24, 2025Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07024212 · 110 enrolled · China, Hong Kong
- Jun 24, 2026Phase 3 study in HypertriglyceridemiaPhase 3 reachedNCT07680829 · 378 planned · China
- Jul 1, 2026Phase 3 study in HypertriglyceridemiaNCT07693777 · 480 planned · China
- Sep 24, 2026Phase 2 study in HypertriglyceridemiaNCT07848880 · 315 planned · China
Ahead
- Apr 2028Primary completion: phase 2 study in HypertriglyceridemiaNCT07848880
- Feb 14, 2029Primary completion: phase 3 study in HypertriglyceridemiaNCT07693777
- Jun 2030Primary completion: phase 3 study in HypertriglyceridemiaNCT07680829
TargetBeta
“DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| efinopegdutide | Johnson & Johnson | phase 2 | 15 |
| AZD9550 | AstraZeneca | phase 2 | 7 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07848880Hypertriglyceridemia · China | 2 | Not yet recruiting | Apr 2028 | 315 |
| NCT07693777Hypertriglyceridemia · China | 3 | Not yet recruiting | Feb 14, 2029 | 480 |
| NCT07680829Hypertriglyceridemia · China | 3 | Not yet recruiting | Jun 2030 | 378 |
| NCT07024212Non-alcoholic Fatty Liver Disease · China, Hong Kong | 2 | Active, not recruiting | Jun 18, 2026 | 110 |
| NCT06555640Hypertriglyceridemia · China | 2 | Completed | Jun 30, 2025 | 79 |
| NCT05378893Obesity, Metabolically Benign · New Zealand | 1 | Completed | Oct 10, 2024 | 153 |
How it is read
Names in the registry
- “DR10624 Injection”, 4 entries
- “DR10624 for injection”, 1 entry
- “DR10624 Subcutaneous Injection”, 1 entry
Codes read as this program: DR10624.
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 4 studies
- Obesity, Metabolically Benign, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.